Ozempic Gastroparesis Attorney: New York Ozempic Gastroparesis Injury Lawyer

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From Health Awareness to Legal Recourse

For decades, the public health conversation around general wellness has emphasized the importance of informed decision-making and awareness of potential risks associated with widely used treatments. This legacy of health literacy has empowered individuals to seek clarity on how medications may affect their bodies over time. In the context of mass production and widespread prescription, the same principles of vigilance apply. As a medication like Ozempic becomes more common in clinical practice, questions naturally arise about its long-term implications. Specifically, reports of gastrointestinal complications, including gastroparesis, have prompted a shift in focus from general health maintenance to specific exposure concerns. For those who have used Ozempic and subsequently developed symptoms such as persistent nausea, vomiting, or abdominal pain, the transition from patient to potential claimant requires careful navigation. This is where the role of a specialized attorney becomes relevant. A New York Ozempic gastroparesis injury lawyer can help individuals understand their legal options when a prescribed treatment leads to unexpected harm. The bridge from general health awareness to occupational or personal exposure risk is built on the same foundation: the right to know and the right to seek recourse when outcomes diverge from expectations.

Understanding Ozempic and Its Gastrointestinal Risks

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. Clinical data from placebo-controlled trials reveal a significantly higher incidence of gastrointestinal adverse reactions among patients receiving Ozempic compared to those on placebo. Specifically, gastrointestinal adverse reactions occurred in 32.7% of patients on Ozempic 0.5 mg and 36.4% on Ozempic 1 mg, versus 15.3% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and diarrhea occurred during dose escalation, and discontinuation due to these reactions was higher in the Ozempic groups (3.1% for 0.5 mg and 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In trials involving Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions were more frequent at the higher dose (34.0% for 2 mg vs. 30.8% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Gastroparesis: Symptoms and Link to Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. The clinical presentation of gastroparesis overlaps with the gastrointestinal adverse effects reported with Ozempic, including dyspepsia, which occurred at rates of 3.5% (0.5 mg) and 2.7% (1 mg) versus 1.9% on placebo, and gastroesophageal reflux disease, reported in 1.9% (0.5 mg) and 1.5% (1 mg) versus 0% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Other gastrointestinal reactions with frequencies below 5% included eructation, flatulence, and gastritis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While the prescribing information does not explicitly list gastroparesis as an adverse reaction, the mechanistic pathway linking GLP-1 receptor agonists to delayed gastric emptying is well established. GLP-1 receptor agonists slow gastric motility by inhibiting vagal nerve activity and reducing antral contractions, which can exacerbate or unmask gastroparesis in susceptible individuals. The dose-dependent increase in gastrointestinal adverse reactions supports a causal relationship between Ozempic exposure and impaired gastric emptying.

Inadequate Warnings and Legal Implications

The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk consideration. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but it does not specifically address the risk of gastroparesis or delayed gastric emptying as a distinct condition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This omission may leave patients and healthcare providers unaware of the potential for severe, persistent gastric dysfunction. The label does note that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported, and caution is advised for patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may be considered inadequate, particularly given the mechanistic plausibility and the frequency of gastrointestinal symptoms that mimic gastroparesis.

Legal Considerations for Affected Patients

For patients who develop gastroparesis after initiating Ozempic, attorney-related considerations are important. The timeline between exposure and documented harm is a key factor in legal claims. Gastrointestinal adverse reactions, including nausea, vomiting, and dyspepsia, typically occur during dose escalation, as noted in clinical trials (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the onset of gastroparesis may be delayed, with symptoms persisting or worsening over weeks to months. Patients who experience severe or prolonged gastrointestinal symptoms should seek medical evaluation, including gastric emptying studies, to confirm a diagnosis of gastroparesis. Documentation of the timing of Ozempic initiation relative to symptom onset is essential for establishing a causal link. Legal considerations for affected patients include the potential for product liability claims based on inadequate warnings or failure to warn. The prescribing information's lack of explicit mention of gastroparesis may support arguments that the manufacturer did not adequately communicate the risk. Patients should consult with an attorney experienced in pharmaceutical litigation to evaluate the strength of their case, including the availability of medical records, prescription history, and expert testimony. The dose-dependent nature of gastrointestinal adverse reactions, as evidenced by higher rates at 2 mg compared to 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), may also be relevant in demonstrating a predictable risk.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it linked to Ozempic?

Gastroparesis is a condition where the stomach empties slowly without a physical blockage, causing nausea, vomiting, and bloating. Ozempic, a GLP-1 receptor agonist, slows gastric motility, which can trigger or worsen gastroparesis. Clinical trials show high rates of gastrointestinal side effects, and the prescribing information does not specifically warn about gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What should I do if I developed gastroparesis after taking Ozempic?

Seek medical evaluation, including gastric emptying studies, to confirm the diagnosis. Document the timeline of Ozempic use and symptom onset. Consult a New York Ozempic gastroparesis injury lawyer to discuss potential product liability claims based on inadequate warnings. Legal action may require medical records and expert testimony.

Why might the warnings about Ozempic and gastroparesis be inadequate?

The prescribing information lists gastrointestinal adverse reactions but does not specifically mention gastroparesis or delayed gastric emptying as a distinct risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Given the mechanistic link and frequency of symptoms, this omission may fail to alert patients and doctors to the potential for severe, persistent gastric dysfunction.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.